Radiation Therapy Insurance Claim Denied? How to Appeal

Radiation therapy is a cornerstone of cancer treatment, used for more than half of all cancer patients at some point during their care. Yet advanced radiation techniques — stereotactic body radiotherapy (SBRT), proton beam therapy, and stereotactic radiosurgery (SRS) — are among the most frequently denied treatment categories by health insurers. These denials are particularly dangerous because they occur during active cancer treatment when delays have direct clinical consequences. NCCN (National Comprehensive Cancer Network) guidelines and ASTRO (American Society for Radiation Oncology) evidence-based clinical policies provide the authoritative clinical standards to challenge these denials.

Why Insurers Deny Radiation Therapy

Advanced technique disputes — SBRT, IMRT, and SRS. An insurer may cover conventional external beam radiation therapy (EBRT) but deny SBRT (CPT 77373, 77385–77387), stereotactic radiosurgery for brain tumors (CPT 77371–77372), or intensity-modulated radiation therapy (IMRT, CPT 77301, 77385–77386). The insurer's argument is typically that conventional radiation achieves "clinically equivalent" tumor control — an argument that ignores critical differences in toxicity profiles, dose delivery precision, treatment duration, and the ability to deliver ablative doses adjacent to critical structures.

Proton therapy denied as clinically equivalent to photon radiation. Proton beam therapy is significantly more expensive than photon-based radiotherapy, making it a primary target for denial. Insurers deny proton therapy by citing cost-equivalence arguments that fail to account for dose reduction to organs at risk — particularly critical for pediatric patients, patients with tumors adjacent to the heart or spinal cord, and those with head and neck cancers where salivary gland sparing directly affects long-term quality of life.

"Experimental" classification contradicting NCCN standards. SBRT for early-stage lung cancer is NCCN Category 1 for medically inoperable patients — the highest level of clinical evidence. SRS for brain metastases is similarly well-established. Classifying these NCCN Category 1 recommendations as "experimental" or "investigational" is clinically indefensible and legally challengeable.

Concurrent chemoradiation denied. Concurrent cisplatin and radiation for cervical cancer (per NCCN CERV guidelines), temozolomide with radiation for glioblastoma multiforme (per NCCN CNS guidelines), or concurrent chemoradiation for locally advanced lung cancer may be denied as "not medically necessary" compared to sequential treatment — contradicting established NCCN Category 1 evidence.

Fraction authorization disputes. Insurers authorize a limited number of radiation fractions and then deny authorization for additional fractions the radiation oncologist determined were clinically necessary to complete the treatment course, forcing treatment interruptions with direct clinical consequences.

How to Appeal a Radiation Therapy Denial

Step 1: Request and Review the Insurer's Clinical Policy Bulletin

Immediately request the insurer's Clinical Policy Bulletin (CPB) for the denied radiation technique. You are legally entitled to this document under ACA Section 2719 (42 U.S.C. § 300gg-19). Compare the CPB's coverage criteria to: (1) NCCN guidelines for your specific cancer type, stage, and anatomical location; and (2) ASTRO Model Policies for the specific radiation technique denied. When the CPB is more restrictive than NCCN — which is often the case — this discrepancy is the central argument for reversal.

Step 2: Obtain a Detailed Letter From Your Radiation Oncologist With Dosimetric Rationale

Your radiation oncologist should write a comprehensive letter that: (1) identifies your cancer diagnosis with ICD-10 code (e.g., C34.11 for upper lobe right malignant neoplasm; C71.9 for brain malignant neoplasm; C53.9 for cervical cancer); (2) explains why the specific technique prescribed is medically necessary for your tumor location, size, and relationship to adjacent critical structures; (3) directly addresses why conventional radiation is clinically inferior in your case — citing organ-at-risk dose constraints, tumor response requirements, or adjacent critical structure proximity; (4) cites the relevant NCCN guideline category; and (5) includes dosimetric comparison data or treatment planning analysis if available.

Step 3: Prepare a Dosimetric Comparison for Advanced Technique Disputes

For SBRT, IMRT, and proton therapy disputes, a dose-volume histogram (DVH) or comparative treatment plan showing radiation dose distribution to the tumor and surrounding organs under both the prescribed technique and the conventional alternative is the most powerful evidence available. Your radiation oncology team's medical physics staff can generate this comparison. Quantitative data showing that conventional radiation would deliver significantly higher dose to the spinal cord, heart, lungs, or bowel than the prescribed technique is clinically compelling and difficult for reviewers to dismiss.

Step 4: Challenge the "Clinically Equivalent" Argument With Organ-at-Risk Data

The insurer's "clinically equivalent" argument assumes that the only metric is tumor control probability — ignoring normal tissue complication probability (NTCP) and long-term toxicity. For each critical structure at risk in your case, document: the dose constraint required to avoid serious toxicity (e.g., spinal cord D1cc < 14 Gy for SRS; heart V25 < 10% for lung SBRT); the dose that the prescribed technique would deliver to that structure; and the dose that conventional radiation would deliver. The clinical difference — reduced risk of radiation myelopathy, radiation pneumonitis, cardiac toxicity, or secondary malignancy — is a medically necessary justification for the advanced technique.

Step 5: File the Internal Appeal Requesting a Radiation Oncologist Peer-to-Peer Review

Submit a formal written appeal including: your radiation oncologist's letter, dosimetric comparison, relevant NCCN guideline pages with category designation highlighted, ASTRO model coverage policy or evidence-based practice statements, and a specific challenge to each criterion in the CPB that is more restrictive than NCCN. Simultaneously request a peer-to-peer review between your radiation oncologist and the insurer's medical director — and insist that the insurer's reviewer be a board-certified radiation oncologist, not a general oncologist or internist. Send the appeal via certified mail.

Step 6: Request External Independent Review Specifying Radiation Oncology Expertise

After an unsuccessful internal appeal, request external review immediately and specify that the external reviewer must be a board-certified radiation oncologist. External reviewers with appropriate specialty expertise, applying NCCN and ASTRO standards, approve radiation therapy appeals at meaningful rates when the clinical rationale, dosimetric evidence, and guideline citations are comprehensive. File simultaneously with your state insurance commissioner or, for ERISA plans, with the DOL's EBSA.

What to Include in Your Appeal

• Denial letter and insurer's Clinical Policy Bulletin for the denied radiation technique
• Cancer diagnosis documentation: pathology report, staging workup, imaging showing tumor location relative to critical structures
• Radiation oncologist's letter citing ICD-10 diagnosis code, NCCN guideline category, and clinical rationale
• Dosimetric comparison or dose-volume histogram showing dose difference to tumor and organs at risk
• NCCN guideline pages for your specific cancer type and technique (with evidence category designation)
• ASTRO model coverage policy or evidence-based practice statement for the denied technique

Fight Back With ClaimBack

A radiation therapy denial during active cancer treatment is among the most urgent insurance appeals you will face — and one of the most winnable when properly documented. NCCN Category 1 designations, ASTRO model coverage policies, and your radiation oncologist's dosimetric evidence provide a clinical foundation that external reviewers with specialty expertise regularly use to reverse these denials. ClaimBack generates a professional appeal letter in 3 minutes, citing NCCN guidelines, ASTRO standards, and the specific legal and clinical provisions that apply to your radiation therapy denial.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal